• Latest News

    December extensions for two cancer medicines

    The listing of MSD's KEYTRUDA (pembrolizumab) will be extended to include its use as a first-line treatment in combination with chemotherapy while Amgen's BLINCYTO (blinatumomab) will be funded for early stage of acute lymphoblastic leukaemia.